CO5690531A2 - Formas de administracion masticables, no comprimidas dosificadas individualmente - Google Patents

Formas de administracion masticables, no comprimidas dosificadas individualmente

Info

Publication number
CO5690531A2
CO5690531A2 CO06043842A CO06043842A CO5690531A2 CO 5690531 A2 CO5690531 A2 CO 5690531A2 CO 06043842 A CO06043842 A CO 06043842A CO 06043842 A CO06043842 A CO 06043842A CO 5690531 A2 CO5690531 A2 CO 5690531A2
Authority
CO
Colombia
Prior art keywords
individually
administration forms
compressed
weight
water
Prior art date
Application number
CO06043842A
Other languages
English (en)
Spanish (es)
Inventor
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Gonzalez Nuria Garcia
Coll Pere Guiro
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5690531(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of CO5690531A2 publication Critical patent/CO5690531A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO06043842A 2003-11-10 2006-05-09 Formas de administracion masticables, no comprimidas dosificadas individualmente CO5690531A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
CO5690531A2 true CO5690531A2 (es) 2006-10-31

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06043842A CO5690531A2 (es) 2003-11-10 2006-05-09 Formas de administracion masticables, no comprimidas dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (https=)
EP (1) EP1682097B1 (https=)
JP (1) JP4879021B2 (https=)
KR (1) KR20060116821A (https=)
CN (1) CN1878542A (https=)
AR (1) AR048050A1 (https=)
AT (1) ATE492270T1 (https=)
AU (1) AU2004290517B2 (https=)
BR (1) BRPI0416215A (https=)
CA (1) CA2548615A1 (https=)
CO (1) CO5690531A2 (https=)
DE (1) DE602004030706D1 (https=)
EC (1) ECSP066553A (https=)
ES (2) ES2235626B1 (https=)
IL (1) IL175285A (https=)
MY (1) MY143793A (https=)
NO (1) NO20062723L (https=)
NZ (1) NZ546375A (https=)
PE (1) PE20050488A1 (https=)
RU (1) RU2369379C2 (https=)
TW (1) TW200526266A (https=)
UA (1) UA90253C2 (https=)
UY (1) UY28586A1 (https=)
WO (2) WO2005048975A1 (https=)
ZA (1) ZA200602416B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CN101686942B (zh) * 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
WO2010150261A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
US20070134318A1 (en) 2007-06-14
BRPI0416215A (pt) 2006-12-26
PE20050488A1 (es) 2005-08-24
UY28586A1 (es) 2005-05-31
CN1878542A (zh) 2006-12-13
ATE492270T1 (de) 2011-01-15
MY143793A (en) 2011-07-15
WO2005048974A2 (en) 2005-06-02
ECSP066553A (es) 2006-12-20
ES2235626B1 (es) 2006-11-01
IL175285A (en) 2011-04-28
WO2005048974A3 (en) 2006-02-23
ES2235626A1 (es) 2005-07-01
AU2004290517B2 (en) 2010-05-27
CA2548615A1 (en) 2005-06-02
TW200526266A (en) 2005-08-16
NO20062723L (no) 2006-06-12
ES2358332T3 (es) 2011-05-09
UA90253C2 (ru) 2010-04-26
JP2007510690A (ja) 2007-04-26
EP1682097A2 (en) 2006-07-26
DE602004030706D1 (de) 2011-02-03
NZ546375A (en) 2009-11-27
AU2004290517A1 (en) 2005-06-02
RU2369379C2 (ru) 2009-10-10
EP1682097B1 (en) 2010-12-22
KR20060116821A (ko) 2006-11-15
WO2005048975A1 (en) 2005-06-02
IL175285A0 (en) 2006-09-05
ZA200602416B (en) 2009-06-24
RU2006120087A (ru) 2007-12-27
AR048050A1 (es) 2006-03-29
JP4879021B2 (ja) 2012-02-15

Similar Documents

Publication Publication Date Title
CO5690531A2 (es) Formas de administracion masticables, no comprimidas dosificadas individualmente
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
ES2829386T3 (es) Parche de administración transdérmica
JP2007510690A5 (https=)
AR048033A1 (es) Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
ATE424815T1 (de) Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
ES2058109T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica antimicrobiana topica.
FI813734L (fi) Farmaceutiska kompositioner
IS5669A (is) Lyfjasamsetning sem mögulegt er að hleypa
TR200102861T2 (tr) Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar.
KR970704464A (ko) 간단한 조성 및 높은 생물 유효성을 갖는 경구 투여용의 신규 사이클로스포린 제형 및 이의 제조방법(Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them)
BR0109036A (pt) Formulações farmacêuticas
ES2062697T3 (es) Procedimiento para la incorporacion en pellets de principios activos protegidos contra la degradacion en la panza de los rumiantes.
ES8205353A1 (es) Un metodo de fabricacion de una composicion farmaceutica de liberacion retardada en formade pastillas que contienen aci-dos acetilsalicilico.
JP2012214454A (ja) 外用剤キット
ATE399001T1 (de) Sphäroide, deren herstellungsverfahren und sphäroidenhaltige arzneimittel
PE20001547A1 (es) Composiciones de betahistina de liberacion controlada
AR093275A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
AR034995A1 (es) Capsula elastica blanda y metodo para su preparacion
AR044420A1 (es) Peliculas de envoltura elasticas
KR20210001695U (ko) 동물성 연질캡슐 손 소독제
EP3823722A1 (en) Devices and methods for ultrasonic delivery of an agent within an oral cavity
MX170641B (es) Procedimiento para preparar una composicion farmaceutica a base de trimebutina

Legal Events

Date Code Title Description
FC Application refused